Cannabidiol's (CBD) safety profile and broad action has made it a popular treatment option
for anxiety and co-occurring sleep disturbance. However, its efficacy in healthy and clinical …

Background Medical cannabinoids differ in their pharmacology and may have different
treatment effects. We aimed to conduct a pharmacology-based systematic review (SR) and …

The pharmacological interventions available for individuals in the early stages of psychosis
are extremely limited. For those at clinical high risk for psychosis, there is no licensed …

Alterations in cannabinoid CB1 receptor (CB1R) are implicated in various psychiatric
disorders. CB1R participates in both depolarization induced suppression of inhibition (DSI) …

The current review evaluates the potential of cannabidiol (CBD) as a promising
pharmacotherapy for social anxiety disorder (SAD). Although a number of evidence-based …

Cannabis use peaks during adolescence and emerging adulthood, and cannabis use
disorder (CUD) is associated with a wide range of adverse outcomes. This is particularly …

Background Evidence suggests that an overlap exists between the neurobiology of
psychotic disorders and the effects of cannabinoids on neurocognitive and neurochemical …

The neurobiological mechanisms underlying the effects of delta-9-tetrahydrocannabinol
(THC) remain unclear. Here, we examined the spatial acute effect of THC on human on …

Rationale Mismatch negativity (MMN) is a candidate endophenotype for schizophrenia
subserved by N-methyl-D-aspartate receptor (NMDAR) function and there is increasing …

Abstract Novel Psychoactive Substances newly introduced on the drug market are
constantly changing patterns of drug consumption. Among these, Synthetic Cannabinoids …